Pipobroman

Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al[1].

Product Specifications

CAS Number

[54-91-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA Alkylator/Crosslinker; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Pipobroman.html

Concentration

10mM

Purity

99.81

Solubility

DMSO : ≥ 36 mg/mL

Smiles

O=C(N1CCN(C(CCBr)=O)CC1)CCBr

Molecular Formula

C10H16Br2N2O2

Molecular Weight

356.05

Precautions

H302, H315, H319, H335

References & Citations

[1]Jean-Jacques Kiladjian, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011 Oct 10;29 (29) :3907-13.|[2]Charles Cassius, et al. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. J Invest Dermatol. 2016 Jun;136 (6) :1302-1305.|[3]Yellin TO. Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10 (11) :605-12.